Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study

John G. Csernansky; Leon Lombrozo; George D. Gulevich; Leo E. Hollister

Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study

John G. Csernansky^*, Leon Lombrozo, George D. Gulevich, Leo E. Hollister

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ ml. As the drug was well tolerated at these doses and as negative symptoms of schizophrenia are difficult to treat, a double-blind, controlled trial of alprazolam is underway to test more rigorously these preliminary results.

Original language	English (US)
Pages (from-to)	349-352
Number of pages	4
Journal	Journal of clinical psychopharmacology
Volume	4
Issue number	6
State	Published - Dec 1984

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a8e72b456c1c4cd8a8bfa9ecea49257c,

title = "Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study",

abstract = "Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ ml. As the drug was well tolerated at these doses and as negative symptoms of schizophrenia are difficult to treat, a double-blind, controlled trial of alprazolam is underway to test more rigorously these preliminary results.",

author = "Csernansky, {John G.} and Leon Lombrozo and Gulevich, {George D.} and Hollister, {Leo E.}",

year = "1984",

month = dec,

language = "English (US)",

volume = "4",

pages = "349--352",

journal = "Journal of clinical psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "6",

}

TY - JOUR

T1 - Treatment of negative schizophrenic symptoms with alprazolam

T2 - A preliminary open-label study

AU - Csernansky, John G.

AU - Lombrozo, Leon

AU - Gulevich, George D.

AU - Hollister, Leo E.

PY - 1984/12

Y1 - 1984/12

N2 - Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ ml. As the drug was well tolerated at these doses and as negative symptoms of schizophrenia are difficult to treat, a double-blind, controlled trial of alprazolam is underway to test more rigorously these preliminary results.

AB - Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ ml. As the drug was well tolerated at these doses and as negative symptoms of schizophrenia are difficult to treat, a double-blind, controlled trial of alprazolam is underway to test more rigorously these preliminary results.

UR - http://www.scopus.com/inward/record.url?scp=0021685012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021685012&partnerID=8YFLogxK

M3 - Article

C2 - 6150950

AN - SCOPUS:0021685012

SN - 0271-0749

VL - 4

SP - 349

EP - 352

JO - Journal of clinical psychopharmacology

JF - Journal of clinical psychopharmacology

IS - 6

ER -

Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this